Lesson
Coronary Disease Spectrum and Assessment
CCD includes fixed plaque, prior infarction or revascularization, nonobstructive ischemia, vasospasm, microvascular dysfunction, and symptom states that can change from stable to acute.
- Atherosclerotic plaque
- Supply-demand mismatch
- Anginal equivalents
- Unstable symptom change
Can remain silent or produce fixed obstruction
Symptoms emerge when reserve is insufficient
Angina can occur without major obstruction
Observed disease determines prevention intensity
Define the coronary phenotype
CCD includes obstructive and nonobstructive coronary disease, prior MI or revascularization, ischemia detected noninvasively, and chronic angina syndromes. Anatomy, physiology, symptoms, ventricular function, and event history each contribute information. A normal-looking major vessel does not exclude coronary dysfunction.
Connect plaque to systemic risk
Coronary plaque is one expression of a diffuse atherosclerotic process. PCI or bypass can restore flow around selected lesions but does not erase plaque elsewhere. Lipid lowering, blood pressure control, tobacco cessation, activity, diabetes therapy, and antithrombotic planning remain necessary after symptom relief or revascularization.
Interpret supply and demand
Myocardial ischemia can result from fixed flow limitation, vasospasm, microvascular dysfunction, tachycardia, hypertension, anemia, hypoxemia, or increased contractility. Chest pressure is common, but dyspnea, fatigue, epigastric discomfort, nausea, or reduced exercise capacity can be anginal equivalents.
Do not diagnose ischemia from a gesture
A clenched fist over the chest can occur with ischemic discomfort, but Levine's sign is neither universal nor sufficiently accurate to establish or exclude coronary disease. Diagnosis integrates symptom probability, ECG, biomarkers when acute disease is possible, prior anatomy, ventricular function, and an appropriate anatomic or functional testing pathway.
Detect the transition to acute care
New rest symptoms, longer or more frequent episodes, a lower exertional threshold, syncope, instability, or poor nitroglycerin response require urgent ACS evaluation. Do not remotely titrate chronic antianginals when the clinical pattern suggests acute plaque disruption or another emergency. Improvement after nitroglycerin does not establish a diagnosis or rule out ACS; the symptom trajectory still determines urgency.
Quick check
Checking for saved practice…
Lesson
Comprehensive Event Prevention
Event prevention requires sustained control of atherosclerotic biology and the conditions that accelerate it, supported by rehabilitation, behavior change, and accessible care.
- Physical activity and rehabilitation
- Tobacco treatment
- Lipid and pressure goals
- Cardiometabolic therapies
Build repeatable rather than idealized plans
Use current risk-based goals
Balance ischemia and bleeding
Make the plan deliverable
Build movement and rehabilitation into care
For patients without contraindications, aim for at least 150 minutes of moderate or 75 minutes of vigorous aerobic activity weekly, plus strength training on at least two days. Reduce sedentary time and refer eligible patients for cardiac rehabilitation. A useful plan accounts for ischemic symptoms, recent events, revascularization, ventricular function, mobility, transport, cost, work, and confidence.
Make nutrition actionable
Build meals around vegetables, fruit, legumes, nuts, whole grains and lean protein. Replace saturated fats with unsaturated fats and fiber-rich foods; the CCD guideline suggests saturated fat below 6% of calories. Avoid trans fat, minimize processed meats and sweetened beverages, and target sodium below 2,300 mg/day, ideally 1,500 mg/day when feasible. Adapt changes to access, preferences and comorbidities.
Measure alcohol exposure accurately
Do not recommend starting alcohol for cardiovascular benefit. For those who drink, less is better; review interactions and conditions that favor abstinence. One U.S. standard drink contains about 14 g of ethanol: 12 fl oz of 5% beer, 5 fl oz of 12% wine, or 1.5 fl oz of 40% spirits. Larger pours or stronger drinks count as more than one.
Treat tobacco dependence as disease
Ask about cigarettes, vaping, smokeless tobacco, and nicotine products. Combine behavioral support with evidence-based cessation medication when appropriate. E-cigarettes are not preferred first-line cessation therapy because long-term safety and sustained use remain concerns.
State the lipid goal and treatment response
Document atherosclerosis and clinical ASCVD history rather than assigning secondary-prevention risk from angina alone. For clinical ASCVD at very high risk, the 2026 goals are LDL-C below 55 mg/dL and non-HDL-C below 85 mg/dL. Other clinical ASCVD patients generally have an LDL-C goal below 70 mg/dL, with further intensification considered by risk. Use a maximally tolerated statin and appropriate nonstatin escalation. High-intensity examples are atorvastatin 40-80 mg or rosuvastatin 20-40 mg daily; check product-specific organ and interaction restrictions. Record baseline and achieved levels, adherence and adverse effects.
Measure pressure before adjusting treatment
Confirm blood pressure with accurate office and home technique. In clinical cardiovascular disease, persistent average BP of at least 130/80 mm Hg supports medication plus lifestyle treatment; the usual goal is below 130/80 mm Hg. Individualize for tolerance, orthostasis, frailty, limited life expectancy and pregnancy. Select therapy around angina, ventricular function, kidney disease, heart rate, and adverse effects. In CCD with hypertension, diabetes, CKD or LVEF at most 40%, an ACE inhibitor, or ARB when ACE-inhibitor intolerant, reduces cardiovascular events. Follow kidney function and potassium.
Consider selected anti-inflammatory prevention
Colchicine may be considered for secondary prevention in CCD; it is not a substitute for foundational treatment. The cardiovascular product Lodoco is 0.5 mg daily. It is contraindicated with strong CYP3A4 or P-gp inhibitors, CrCl below 15 mL/min, severe hepatic impairment, pre-existing blood dyscrasias or product hypersensitivity. Its interaction table includes ranolazine. Review the entire regimen before adding it. New gastrointestinal symptoms can signal toxicity; muscle weakness or pain also needs evaluation, especially with statins. Do not copy a gout-flare regimen.
Include vaccination in cardiovascular prevention
Recommend annual influenza vaccination. Review pneumococcal and COVID-19 vaccination against the current public-health schedule, prior doses, age and comorbidities. A recommendation to review vaccines does not mean every patient needs the same product or an extra dose at every visit.
Use cardiometabolic outcome therapy
Selected SGLT2 inhibitors and GLP-1 receptor agonists provide cardiovascular or heart-failure benefit in appropriate populations beyond glucose lowering alone. Match the exact product to diabetes, HF, CKD, obesity, ASCVD goal, organ function, safety, and access rather than treating broad class labels as interchangeable.
Match empagliflozin to the outcome
Jardiance reduces cardiovascular death in adults with type 2 diabetes and established cardiovascular disease; its HF and CKD indications are separate. The adult outcome dose is 10 mg each morning, with or without food. Increasing to 25 mg is for additional glycemic control. Assess renal function and correct volume depletion. Teach genital/urinary infection precautions and ketoacidosis symptoms, which can occur without marked hyperglycemia. Hold at least three days before surgery or prolonged-fasting procedures when possible; resume when clinically stable and eating. A glycemic eGFR restriction is not automatically the restriction for every indication.
Use the correct semaglutide indication and formulation
Wegovy can reduce major cardiovascular events in adults with established cardiovascular disease and overweight or obesity; diabetes is not required. For injection, start 0.25 mg weekly and escalate every four weeks through 0.5, 1 and 1.7 mg; cardiovascular maintenance is 2.4 mg weekly (recommended) or 1.7 mg according to response and tolerability. Delay escalation if needed. Oral Wegovy has a separate daily regimen. Avoid duplicate GLP-1 therapy. Personal/family medullary thyroid carcinoma, MEN2 or serious product hypersensitivity contraindicates use; severe gastroparesis is a not-recommended precaution.
Quick check
Checking for saved practice…
Lesson
Antithrombotic Strategy
Long-term single antiplatelet therapy, post-PCI DAPT, P2Y12 monotherapy, and oral-anticoagulant overlap solve different thrombotic problems and carry different bleeding costs.
- Single antiplatelet therapy
- DAPT after PCI
- Short DAPT strategies
- Oral anticoagulation overlap
Common long-term CCD foundation
Duration follows presentation and risk
Avoid indefinite bleeding burden without benefit
Never interrupt a recent stent regimen casually
Use single antiplatelet therapy for the right foundation
Aspirin 81 mg daily (75-100 mg range) is a common long-term secondary-prevention therapy when no contraindication or oral-anticoagulant strategy changes the plan. Clopidogrel can be an alternative in selected patients. Review prior MI, PCI, CABG, stroke, bleeding, ulcer disease, anemia, NSAIDs, and allergy.
Connect the antiplatelet target to formulation
Aspirin irreversibly inhibits platelet COX-1, reducing thromboxane-mediated aggregation. Clopidogrel acts through irreversible P2Y12 inhibition after activation. Aspirin formulations are not interchangeable for rapid treatment: the extended-release product Durlaza is labeled 162.5 mg once daily, swallowed whole, and is not for rapid-onset MI or pre-PCI treatment. Do not substitute an extended-release capsule for an acute-care aspirin loading plan.
Counsel about aspirin harm, including coated products
Enteric coating does not remove the labeled serious stomach-bleeding warning. Review prior ulcers, other NSAIDs, anticoagulants, steroids and alcohol exposure. Vomiting blood, black or bloody stools, faintness or persistent abdominal pain needs urgent assessment. Ringing ears or hearing changes also warrant evaluation. Review aspirin/NSAID reactions and asthma history; wheezing, facial swelling or shock can indicate a severe reaction. Children or teenagers with viral illness should not self-use aspirin because of Reye syndrome risk.
Check clopidogrel activation and interactions
Maintenance dosing is 75 mg daily. CYP2C19 activates this prodrug; poor metabolizers may need another P2Y12 inhibitor. Avoid omeprazole and esomeprazole; separating doses does not resolve the interaction. Pantoprazole has less effect. Strong CYP2C19 inducers such as rifampin increase platelet inhibition and bleeding risk; avoid them. Repaglinide exposure also increases: avoid the combination.
Plan interruptions and recognize harm
Active pathological bleeding or product hypersensitivity contraindicates clopidogrel. For necessary surgery with major bleeding risk, its label recommends interruption five days beforehand when possible and resumption after hemostasis. Obtain the coronary team's plan first. Thrombocytopenia with hemolysis or neurological/renal abnormalities raises concern for TTP and needs urgent evaluation.
Make DAPT time limited and explicit
For PCI performed for CCD without an oral-anticoagulant indication, the usual plan is aspirin plus clopidogrel for 6 months, then one antiplatelet. ACS has a different default: at least 12 months of DAPT when bleeding risk is not high. Duration depends on whether the presentation was chronic or acute, PCI complexity, prior stent thrombosis, bleeding risk, oral anticoagulation, and upcoming procedures. A stop date is a clinical decision, not an administrative detail.
Use shortened regimens selectively
Selected DES recipients with CCD may transition after 1 to 3 months of DAPT to P2Y12 monotherapy for at least 12 months to reduce bleeding. This is not a universal schedule for complex anatomy or high thrombotic risk. The interventional plan, presentation, device, adherence, and bleeding context determine suitability.
Separate bypass care from stent care
After CABG, aspirin is continued indefinitely. Adding clopidogrel or ticagrelor for one year may improve vein-graft patency in selected patients; it is not an automatic requirement for every elective CABG. Review an ACS indication separately. Confirm the surgeon's postoperative instructions rather than applying a stent calendar to a bypass graft.
Distinguish vascular prevention from therapeutic anticoagulation
For high recurrent ischemic risk with low-to-moderate bleeding risk and no indication for DAPT or therapeutic anticoagulation, consider rivaroxaban 2.5 mg twice daily plus aspirin 81 mg daily. This vascular dose does not replace an AF or VTE treatment regimen. The 2.5 mg tablet can be taken with or without food. Kidney disease still matters: CAD/PAD studies excluded CrCl below 15 mL/min, had limited data at 15-30 mL/min, and provide no clinical outcome evidence for dialysis patients. Review bleeding, organ function and interactions before prescribing.
Minimize unnecessary overlap with anticoagulation
For elective CCD PCI in a patient requiring a DOAC, the guideline sequence is 1 to 4 weeks of aspirin plus clopidogrel alongside the DOAC, followed by clopidogrel as the only antiplatelet for 6 months alongside the DOAC. This is not clopidogrel replacing anticoagulation. Document the aspirin stop date and subsequent review. In AF with CCD more than one year after revascularization, or CAD not requiring revascularization, oral anticoagulation alone is recommended when there is no history of stent thrombosis. Review any separate acute antiplatelet indication before simplifying therapy.
Quick check
Checking for saved practice…
Lesson
Antianginal Pharmacotherapy
Antianginal therapy improves symptoms by reducing demand, increasing supply, or changing cellular ischemic stress. Drug choice follows hemodynamics, ventricular function, rhythm, interactions, and the patient's symptom goal.
- Beta blockers and calcium channel blockers
- Nitrates
- Ranolazine
- Combination and safety
Reduce rate, contractility, or both
DHPs reduce afterload; nitrates reduce preload and can relieve coronary spasm
Inhibits late sodium current; exact antianginal mechanism remains uncertain
Treat persistent symptoms by mechanism
Choose the first agent from physiology
A beta blocker or calcium channel blocker is commonly selected first, and a long-acting nitrate is another effective option. Beta blockers reduce heart rate and contractility. Non-DHP calcium channel blockers also slow rate but can worsen systolic dysfunction. DHP agents vasodilate without the same nodal effect.
Separate beta-blocker indications
After more than one year following MI, reassess the need for beta blockade when there is no history of or current LVEF at most 50%, no angina, arrhythmia, uncontrolled hypertension or other indication. Reassessment is not an automatic stop order: a recovered ejection fraction does not erase prior ventricular dysfunction. In CCD without prior MI or LVEF at most 50%, beta blockade has no established event-reduction benefit without another indication. Symptom relief can still justify treatment. Avoid abrupt withdrawal.
Treat vasospasm as a distinct mechanism
Rest symptoms with documented or strongly suspected epicardial spasm call for mechanism-directed therapy. Calcium channel blockers and nitrates are central options, along with smoking cessation and avoidance of cocaine or other vasoconstrictive triggers. A routine beta-blocker-centered exertional-angina pathway should not be assumed to treat vasospasm.
Dose ranolazine deliberately
Start extended-release tablets at 500 mg twice daily; the maximum is 1,000 mg twice daily. Swallow whole, with or without food. Skip a missed dose without doubling. This is chronic therapy, not rescue treatment.
Apply interaction limits
Strong CYP3A inhibitors, CYP3A inducers and cirrhosis contraindicate ranolazine. With diltiazem or verapamil, limit it to 500 mg twice daily. Limit simvastatin to 20 mg/day; with ranolazine 1,000 mg twice daily, limit metformin to 1,700 mg/day. Review digoxin and other interacting drugs.
Distinguish renal risk from routine monitoring
QT prolongation is dose related. Monitor kidney function after starting and periodically when creatinine clearance is below 60 mL/min. Acute renal failure has occurred below 30; discontinue and treat if it develops.
Add by a different mechanism
Persistent symptoms can improve when a second antianginal from another class is added. Ranolazine is useful when heart rate or blood pressure limits other drugs, but CYP3A interactions, QTc, liver and kidney context, dizziness, and constipation require review. Refractory symptoms may prompt revascularization evaluation.
Quick check
Checking for saved practice…
Lesson
Nitrate Formulations, Rescue, and Daily Schedules
Separate rapid relief from prevention. Match the instructions to the actual tablet, spray, ointment or oral formulation, and write down when emergency help is needed.
- Rescue dose limits
- Product-specific administration
- Tolerance and dose-free intervals
- Dangerous interactions
14 hours on; 10 hours off before the next morning
7 hours between daytime doses; 17 hours overnight
Once daily; do not copy the IR schedule
Example angina schedule with a 14-hour overnight gap
Use nitrates safely
Short-acting nitroglycerin treats episodes and can be used before predictable exertion. Long-acting nitrates require a nitrate-free interval to limit tolerance. Teach seated use, storage, headache, hypotension, and emergency thresholds. PDE5 inhibitors and riociguat can create dangerous hypotension with nitrates.
Give a specific tablet instruction
For prescribed Nitrostat 0.3, 0.4 or 0.6 mg tablets, dissolve one under the tongue or in the cheek pouch while seated. Do not chew or swallow it. Repeat at 5-minute intervals if needed, with no more than three tablets in 15 minutes. For predictable exertion, a prescribed dose may be taken 5-10 minutes beforehand. Keep tablets in their tightly closed original glass container. Burning or tingling does not establish tablet potency; never use the sensation to decide whether the dose worked.
Make emergency activation explicit
Provide a written, individualized rescue plan. New severe or otherwise concerning symptoms warrant immediate emergency assessment. If symptoms are unimproved or worse 5 minutes after the first nitroglycerin dose, call 911; do not make completing three doses a prerequisite for emergency help. Symptoms that return after relief also warrant emergency activation. Follow the dispatcher's advice while help is coming.
Separate patch prevention from rescue
Nitro-Dur is preventive treatment, with a labeled starting release rate of 0.2-0.4 mg/hour. Plan 12-14 hours with the patch on and 10-12 hours off each day. Continuous wear can produce tolerance that increasing the dose does not reliably overcome. For a 14-hour schedule, application at 8 AM means removal at 10 PM. Apply to clean, dry, relatively hair-free skin; avoid damaged skin, folds and sites below the elbows or knees. Rotate sites. A patch acts too slowly to stop an acute episode.
Use the named spray's instructions
Nitrolingual Pumpspray delivers 0.4 mg per spray. Use one or two sprays onto or under the tongue at onset; repeats are approximately 5 minutes apart, with a maximum of three total sprays in 15 minutes. Two initial sprays therefore leave only one additional spray within that limit. Apply the emergency plan above. Prime this product with five sprays before first use; after six weeks without use, re-prime with one spray, and after three months with up to five. Priming is away from the mouth. Do not inhale the medicine or rinse or spit for 5-10 minutes afterward. Check the specific device instructions rather than transferring this priming schedule to another brand.
Recheck technique when changing spray devices
NitroMist also delivers 0.4 mg per spray, but its label specifies ten priming sprays before first use and two re-priming sprays after more than six weeks without use. Do not shake it. Aim priming sprays away from people; administer treatment onto or under the tongue without inhaling. The treatment ceiling is three total sprays in 15 minutes, with approximately five minutes between administrations. Keep its flammable aerosol away from flames. The identical drug strength does not make its preparation instructions interchangeable with Nitrolingual.
Count powder packets separately from doses
GoNitro's labeled packet contains 0.4 mg. A prescribed initial dose can be one or two packets under the tongue, followed by one additional packet every five minutes if needed, with no more than three packets in 15 minutes. Empty the packet under the tongue while seated, close the mouth, and let the powder dissolve before swallowing. Do not rinse or spit for five minutes. The emergency activation plan still applies. These product examples describe labeled technique; verify the product actually dispensed and its current instructions.
Measure preventive ointment accurately
For Nitro-Bid 2%, one labeled starting regimen is a half-inch ribbon, containing 7.5 mg, on waking and again six hours later. Use its ruled applicator to measure and spread the ointment lightly on the skin; do not rub it in. Secure and cover the applicator. Arrange removal so the daily regimen includes 10-12 hours without nitrate exposure. A foil packet contains approximately a one-inch tube dose, so it is not interchangeable with the half-inch starting dose. This preventive formulation is not acute rescue treatment.
Schedule immediate-release mononitrate asymmetrically
The labeled isosorbide mononitrate immediate-release regimen is 20 mg twice daily, seven hours apart, such as 8 AM and 3 PM. That leaves 17 hours between the afternoon dose and the next morning's dose. Do not interpret twice daily as every 12 hours for this regimen. The interval limits tolerance; it does not guarantee that tolerance is eliminated or provide round-the-clock symptom coverage. This oral preventive product is not a substitute for rapid rescue nitroglycerin.
Ask which PDE5 inhibitor and when it was taken
The 2025 ACS guideline advises avoiding nitrates within 12 hours of avanafil, 24 hours of sildenafil or vardenafil, and 48 hours of tadalafil. These intervals do not authorize patients to combine medicines on their own. Regular and intermittent nitrates remain contraindicated with PDE5 inhibitor use. Ask about medicines used for pulmonary hypertension or urinary symptoms as well as erectile dysfunction, and document the last dose.
Keep emergency exceptions under medical supervision
Avanafil and tadalafil labeling allows consideration of a medically necessary nitrate in a life-threatening situation only after at least 12 and 48 hours, respectively, with close medical supervision and hemodynamic monitoring. A patient with chest pain after a PDE5 inhibitor should seek emergency help and tell responders the drug and last dose, rather than self-administer nitroglycerin or wait at home for an interval to expire. Daily tadalafil creates continuing exposure; a low daily dose does not remove the interaction.
Recognize tolerance and contraindications
Excessive sublingual use can also produce tolerance; long-acting nitrates may reduce the rescue response. Nitrostat is contraindicated with PDE5 inhibitors or riociguat, severe anemia, increased intracranial pressure, nitrate hypersensitivity, and circulatory failure or shock. Hypotension can occur at therapeutic doses.
Identify the preventive nitroglycerin capsule
Nitro-Time extended-release capsules contain 2.5, 6.5 or 9 mg. They act too slowly for an acute attack. The label describes trial starting regimens of 2.5-6.5 mg three or four times daily, adjusted for symptoms and adverse effects, but it also requires a daily nitrate-free interval. Do not turn that frequency into automatic around-the-clock dosing. The precise minimum interval for these capsules is not established; the label cites 10-12 hours from other nitroglycerin formulations. Clarify the actual schedule with the prescriber rather than promising 24-hour protection.
Keep extended-release mononitrate on its morning schedule
Start isosorbide mononitrate extended-release at 30 or 60 mg once daily on waking. After several days, the dose may be increased to 120 mg daily; rarely, 240 mg is required. Do not crush or chew. The cited label permits half of its 60 mg tablet to provide 30 mg, but splitting must be checked against the dispensed product. Do not transfer the immediate-release twice-daily schedule to this formulation.
Build dinitrate dosing around a long overnight gap
For immediate-release oral isosorbide dinitrate used for angina, the labeled starting dose is 5-20 mg two or three times daily; maintenance is generally 10-40 mg two or three times daily. Schedule at least 14 hours each day without a dose to limit tolerance. The label gives 8 AM, 2 PM and 6 PM as an example: 6 PM to 8 AM is 14 hours. Three times daily does not mean every eight hours here. This angina schedule should not be substituted for a separately prescribed hydralazine-dinitrate heart-failure regimen.
Quick check
Checking for saved practice…
Lesson
Testing, Revascularization, and INOCA
Testing answers a changed clinical question. Revascularization treats selected anatomic and physiologic problems, while INOCA requires recognition of coronary dysfunction beyond large-vessel obstruction.
- Actionable test selection
- No routine surveillance
- Symptom-driven revascularization
- Microvascular and vasospastic disease
Reassess when the clinical state changes
Choose the modality for the question
Use anatomy, physiology, symptoms, and preference
Do not image stable patients without a reason
Test because the clinical state changed
New symptoms, reduced function, new ventricular dysfunction, an interval event, or a specific treatment decision can justify anatomic or ischemic evaluation. Test choice depends on exercise capacity, ECG interpretability, kidney function, contrast allergy, radiation, body habitus, prior anatomy, and local expertise.
Separate acute biomarkers from stable testing
When acute myocardial injury is suspected, high-sensitivity cardiac troponin is the preferred biomarker within a structured acute-care pathway. A list of possible investigations is not a standing order for every stable outpatient. Match testing to current symptoms and risk; some low-risk chest-pain presentations need no urgent cardiac imaging.
Choose exercise or pharmacologic stress intentionally
Exercise testing adds functional capacity and symptom information when the patient can exercise and the selected modality can answer the question. Pharmacologic stress is used when exercise is not feasible or when the imaging method requires it. The stress agent, imaging modality, contraindications, caffeine or medicine preparation, and rescue plan must be matched rather than selected from one generic list.
Distinguish flow stress from demand stress
Exercise and dobutamine increase cardiac workload through heart rate and contractility. Regadenoson instead activates adenosine A2A receptors to increase coronary blood flow. Perfusion imaging detects differences in flow response between territories. These mechanisms are not interchangeable: a pharmacologic stress test does not always work by making the heart demand more oxygen.
Avoid calendar-based surveillance
Routine periodic anatomic or ischemic testing is not recommended when symptoms and functional status are unchanged. Low-value surveillance can produce false positives, incidental findings, unnecessary invasive procedures, contrast exposure, radiation, and cost.
Use revascularization for a defined objective
When lifestyle-limiting angina persists despite guideline-directed therapy and anatomy is amenable, PCI or CABG can improve symptoms. Anatomy, ischemic physiology, diabetes, ventricular function, kidney disease, procedural risk, prognosis, and preference determine the approach. Benefits are not limited to symptoms in every population: significant left-main disease, or multivessel disease with LVEF at most 35%, can support CABG plus medical therapy for survival benefit. Heart Team assessment determines suitability. Prevention continues afterward.
Recognize INOCA
Ischemia with nonobstructive coronary arteries can reflect microvascular dysfunction, epicardial spasm, endothelial dysfunction, or mixed mechanisms. A nonobstructive angiogram does not make symptoms imaginary. Mechanism-directed testing and therapy can improve function and quality of life. PET or stress CMR can assess perfusion and flow reserve; selected patients need invasive coronary function testing to distinguish mechanisms. Do not assume that one normal anatomic study excludes dysfunction.
Match nonobstructive treatment to the mechanism
Vasospasm favors calcium channel blockers and nitrates. Microvascular angina may call for beta blockade and ACE-inhibitor or ARB therapy, selected for physiology and comorbidities. Plaque burden and overall risk determine lipid prevention; a nonobstructive finding alone does not mandate aspirin for everyone. Review bleeding risk, established atherosclerosis and other antithrombotic indications.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 116 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- DailyMed. Aspirin 81 mg enteric-coated tablet safety warnings
- DailyMed. Durlaza formulation, mechanism and rapid-onset limitation
- AHA. 2025 nonobstructive coronary disease statement: key recommendations
- Montero-Pérez et al. Diagnostic validity of hand gestures in chest pain (2017)
- DailyMed. Jardiance indications, dosing and safety
- DailyMed. Wegovy cardiovascular indication and formulation-specific dosing
- AHA. 2021 chest pain guideline key recommendations
- NIAAA. Standard drinks and alcohol counseling
- AHA. 2025 high blood pressure guideline key recommendations
- DailyMed. Lodoco cardiovascular dosing, contraindications and interactions
- AHA. 2026 dyslipidemia guideline key recommendations
- AHA. 2026 secondary prevention after CABG update
- ACC. 2023 AF guideline perspectives: anticoagulation in stable coronary disease
- DailyMed. Plavix dosing, warnings and interactions
- AHA/ACC. 2023 CCD guideline slide set, antithrombotic recommendations
- AHA/ACC. 2021 revascularization guideline slide set, post-CABG antiplatelets
- AHA. 2025 ACS guideline announcement and DAPT duration
- DailyMed. Xarelto prescribing information, CAD dosing and renal evidence
- DailyMed. Nitro-Time extended-release capsules, May 2026 labeling
- 2025 ACS guideline: nitrate interaction intervals
- Avanafil prescribing information: nitrate contraindication and emergency precautions
- Tadalafil prescribing information: nitrate contraindication and emergency precautions
- DailyMed. NitroMist labeled dosing and device preparation
- DailyMed. GoNitro labeled dosing and packet administration
- DailyMed. Isosorbide mononitrate extended-release dosing
- DailyMed. Isosorbide dinitrate immediate-release dosing
- DailyMed. Nitrolingual Pumpspray prescribing information
- DailyMed. Nitro-Bid 2% prescribing information
- DailyMed. Isosorbide mononitrate immediate-release prescribing information
- DailyMed. Nitrostat prescribing information
- DailyMed. Nitro-Dur prescribing information and application instructions
- MedlinePlus. Angina: when you have chest pain
- DailyMed. Ranolazine extended-release tablets, July 2026 prescribing information
- DailyMed. Regadenoson mechanism and coronary blood-flow response
- ASNC. Dobutamine stress-testing practice points
- AHA and ACC. 2023 Chronic Coronary Disease Guideline
- American Heart Association. Chronic Coronary Disease Top Things to Know
- AHA and ACC. 2026 Dyslipidemia Guideline
- AHA and ACC. 2021 Chest Pain Guideline
- American Heart Association. 2025 Nonobstructive Coronary Disease Scientific Statement
- DailyMed. Nitroglycerin Sublingual Tablets Prescribing Information